# APONVIE® (aprepitant) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/aprepitant

> The FDA approved APONVIE® (aprepitant), sponsored by HERON THERAPEUTICS, INC. /DE/ (HRTX), on March 6, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is APONVIE® (aprepitant) FDA approved?

Yes. The FDA approved APONVIE® (aprepitant), sponsored by HERON THERAPEUTICS, INC. /DE/ (HRTX), on March 6, 2023. Press release filed with the SEC (EX-99): "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." [Calendar and source filings](https://sec-api.dev/pdufa/aprepitant)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-073502, https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/hrtx-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/pdufa/aprepitant#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | APONVIE® (aprepitant) |
| Codes |  |
| Sponsor | HERON THERAPEUTICS, INC. /DE/ (HRTX) https://sec-api.dev/companies/hrtx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2024-11-12, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-263617): "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." https://www.sec.gov/Archives/edgar/data/818033/000119312525263617/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-105474): "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." https://www.sec.gov/Archives/edgar/data/818033/000095017025105474/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063973): "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." https://www.sec.gov/Archives/edgar/data/818033/000095017025063973/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-028372): "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." https://www.sec.gov/Archives/edgar/data/818033/000095017025028372/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124626): "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." https://www.sec.gov/Archives/edgar/data/818033/000095017024124626/hrtx-ex99_1.htm

### March 6, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-01-09, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073502): "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-452721): "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." https://www.sec.gov/Archives/edgar/data/818033/000119312526452721/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341300): "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." https://www.sec.gov/Archives/edgar/data/818033/000119312526341300/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-215752): "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/hrtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-008631): "APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023." https://www.sec.gov/Archives/edgar/data/818033/000119312526008631/hrtx-ex99_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/aprepitant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "APONVIE® (aprepitant) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/aprepitant

```bibtex
@misc{secapidev_pdufa_aprepitant_20261116,
  title        = {APONVIE® (aprepitant) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/aprepitant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_aprepitant_20261116","title":"APONVIE® (aprepitant) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/aprepitant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
